(VIANEWS) – The Market ended the session with MITHRA (MITRA.BR) rising 16.33% to €3.17 on Tuesday, following the last session’s upward trend. BEL 20 slid 0.76% to €3,852.26, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.
MITHRA’s last close was €2.73, 83.36% below its 52-week high of €16.38.
About MITHRA
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
Earnings Per Share
As for profitability, MITHRA has a trailing twelve months EPS of €-2.25.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -138.93%.
Volume
Today’s last reported volume for MITHRA is 790953 which is 199.7% above its average volume of 263911.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MITHRA’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
MITHRA’s stock is valued at €3.17 at 21:38 EST, way below its 52-week high of €16.38 and way higher than its 52-week low of €2.28.
Moving Average
MITHRA’s value is above its 50-day moving average of €3.11 and way below its 200-day moving average of €5.57.
More news about MITHRA (MITRA.BR).
